MONTREAL, /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...
Bitcoin has remained uncorrelated with the global M2 money supply since mid-2025, and the prolonged divergence has fueled ...
AEW's booking of Powerhouse Hobbs wasn't always perfect, and on the back of his reported exit it makes sense to look at Tony ...
Arthur Hayes says tight dollar liquidity hurt Bitcoin in 2025 and expects easing credit, Fed action, and lower rates to ...
Effectively, putting aside the execution challenges of reducing liquidity to buy and hold more MBS debt, by raiding the ...
Bitcoin’s (BTC) 52-week correlation with gold reached zero for the first time since mid-2022 and may turn negative by the end ...
Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...
Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...
The diagnosis and management of invasive fungal infections in adult patients with hematological malignancies remains a ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback